Navigation Links
Development and Commercialization of Antibacterial Drugs to Speed Up
Date:3/31/2015

LONDON, March 31, 2015 /PRNewswire/ -- The growing threat posed by multi-drug resistant gram-negative organisms (MDR-GNBs) is lending a sense of urgency to the development of antibacterial drugs worldwide. Upcoming regulatory reforms to lower R&D costs and provide incentives for new drug identification will create attractive opportunities for pharmaceutical manufacturers.

Logo - http://photos.prnewswire.com/prnh/20150331/195565LOGO

New analysis from Frost & Sullivan, A Product and Pipeline Analysis of the Antibacterial Drugs Market, finds that nearly 80 percent of drugs currently in the pipeline are from smaller pharmaceutical and biotech companies, of which half do not have any commercialized products in the market. GlaxoSmithKline (www.gsk.com), AstraZeneca (www.astrazeneca.com) and Merck & Co (www.merck.com) are the only three established pharmaceutical organizations in the antibacterial drug space.

For complimentary access to more information on this research, please visit: http://corpcom.frost.com/forms/EU_PR_AZanchi_MABA-52_20Mar15.

"Thirty eight antibacterial drugs currently under development have the potential to address many, but not all, resistant bacteria," said Frost & Sullivan Healthcare Senior Research Analyst Aiswariya Chidambaram. "Plazomicin and Eravacycline are two emerging compounds that have a broad-spectrum activity against most MDR-GNBs."

Discovering new antibacterial drugs and identifying novel compounds that can successfully target bacteria is scientifically challenging. Given the high probability of failure and steep research and development (R&D) costs, big pharma companies that were once leaders are closing down their antibacterial research facilities.

Agencies such as the Food and Drug Administration (FDA) and the Infectious Diseases Society of America are deploying several initiatives to lure companies back into antibacterial R&D. The recently implemented Generating Antibiotic Incentives Now (GAIN) Act is expected to facilitate more efficient clinical studies and reduce barriers to market entry. In Europe, the Innovative Medicines Initiative (IMI) has launched two projects – Combatting Bacterial Resistance in Europe (COMBACTE) and TRANSLOCATION (molecular basis of the bacterial cell wall permeability) – that showcase an unprecedented partnership between industry, biotech organizations, and academia to fight antibiotic resistance.

"Further, collaborations in the form of public-private partnerships among industry, academia, investors and key opinion leaders will effectively address the vast unmet clinical and commercial needs in the antibacterial drugs market and quicken the journey towards commercialization," concluded Chidambaram.

A Product and Pipeline Analysis of the Antibacterial Drugs Market is part of the Life Sciences Growth Partnership Service program. Frost & Sullivan's related studies include: A Competitive Analysis of the Global Breast Cancer Therapeutics Market, A Product and Pipeline Analysis of the Opioid Therapeutics and Drug Delivery Market, A Product and Pipeline Analysis of the Lung Cancer Therapeutics Market, and Product and Pipeline Analysis of the Global Rheumatoid Arthritis Therapeutics Market. All studies included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact
Anna Zanchi
Corporate Communications – Europe
P: +39.02.4851 6133
E: anna.zanchi@frost.com 
http://www.frost.com

 


'/>"/>
SOURCE Frost & Sullivan
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. RuiYi and Genor BioPharma Collaborate on Development in China of RYI-008, a Novel Therapeutic for Autoimmune Diseases and Cancer
2. Asmacure to Present Four Posters on Novel Pulmonary Development Compound ASM-024 at American Thoracic Society 2013 International Conference
3. Heptares Augments Business Development Capabilities in Japan and Other Asian Territories
4. Cempra Awarded $58 Million Contract to Develop Antibiotic for Pediatric Use and Biodefense by Biomedical Advanced Research and Development Authority (BARDA)
5. Metabolic Solutions Development Company announces publication of data describing potential for new drugs to maintain pancreatic beta-cells in treating diabetes
6. Cannabis Science Appoints Clinical Development Expert, Dr. Dorothy Bray, as Chief Executive Officer (CEO) and Director, Focusing on CS-TATI-1 and Building Companys Drug Development Pipeline
7. QIAGEN Expands Pipeline of Promising New Biomarkers for Development of Personalized Healthcare Companion Diagnostics
8. Global Role of Market Research Supports Need for Training and Development Programs
9. NeuroDerm Awarded $1M by The Michael J. Fox Foundation for the Clinical Development of ND0612 for Parkinsons Disease
10. Goodwin Biotechnology Announces Process Development Sub-Contract for an Anthrax Vaccine
11. Development of New Technologies Spurs Molecular Diagnostic Test Volumes in Asia-Pacific, Finds Frost & Sullivan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2019)... (PRWEB) , ... June 15, 2019 , ... ... a stem cell clinic offering state-of-the-art treatment with cutting-edge technology, has opened. ... details about the game-changing healing capabilities of regenerative medicine. , “Using the ...
(Date:6/13/2019)... ... June 13, 2019 , ... BESANA ... to a wellness center dedicated to realizing your optimal health, inside and out. ... Skin Aesthetics, BESANA Health & Wellness offers a range of wellness services, including ...
(Date:6/13/2019)... ... , ... Homecare Homebase (HCHB) the nation’s leader in mobile ... of the HCHB Intelligence Suite, at the company’s annual Users Conference this week ... efficient routing, mapping and scheduling for home health agencies to automate the scheduling ...
Breaking Medicine Technology:
(Date:6/13/2019)... ... June 13, 2019 , ... Pure Ratios, the creator of ... company, Driven Deliveries, Inc., the only publicly traded cannabis delivery service in the ... of California with overnight cannabis delivery to major thriving markets such as the ...
(Date:6/13/2019)... ... 2019 , ... In two nationally representative surveys of parents and principals on ... movement Active Schools aimed to gain a better understanding of the ... , The U.S. Department of Health and Human Services recommends that children and adolescents ...
(Date:6/13/2019)... ... 2019 , ... Many people with back pain that radiates down their legs ... widely misunderstood and so are its treatments, according to Kaliq Chang, MD, double board-certified ... , “Sciatica is commonly used to describe nerve-like pain traveling down the legs, often ...
(Date:6/13/2019)... AUSTIN, Texas (PRWEB) , ... June 13, 2019 ... ... welcomed Kaitey Morgan, RN, BSN, CRNI and Charles “Charlie” Schadewald as the newest ... Charlie both served as members of NICA’s Advisory Committee. The NICA Advisory Committee ...
(Date:6/12/2019)... ... 2019 , ... Recent research shows that a lack of ... , Researchers from the University of Chichester in the U.K. conducted ... people who have dementia and experienced a declining relationship with those patients. The ...
Breaking Medicine News(10 mins):